1. Finlay, A. Y., & Khan, G. K. (1994). Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210–216.
2. Basra, M. K., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008). The Dermatology Life Quality Index 1994–2007: A comprehensive review of validation data and clinical results. British Journal of Dermatology, 159(5), 997–1035. doi: 10.1111/j.1365-2133.2008.08832.x .
3. European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. London, 18 November 2004. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf . Accessed: 02 July 2015.
4. Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E., Nast, A., et al. (2011). Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research, 303(1), 1–10. doi: 10.1007/s00403-010-1080-1 .
5. Pathirana, D., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P. I., Nast, A., et al. (2009). European S3-guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 23(Suppl 2), 1–70. doi: 10.1111/j.1468-3083.2009.03389.x .